Nightingale. Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia. Ann Pharmacother. 2011 Oct;45(10):1248-55. Epub 2011 Sep 6.
Ofatumumab is a human immunoglobulin antibody that binds to B-lymphocytes expressing CD-20 cell surface antigens. Ofatumumab activity has also been shown in a variety of other malignant and nonmalignant conditions, including non-Hodgkin lymphoma, rheumatoid arthritis, and multiple sclerosis.
“Rituximab and Ocrelizumab are not the only kids on the block!”
“Do you think competition will speed up the delivery of drugs to MS’ers?”
“I wish!”
I hope competition doesn't slow the development of new treatments. And I hope having more drugs will bring prices down or at least stop price increases.
Yes, I just want drugs that actually work. Drugs that stop, perhaps even reverse MS progression.In your wise words Prof G: "I wish!"